Want to see TIL full AI Analyst Report?

Instil Bio (TIL) Price & Analysis

370 Followers

TIL Stock Chart & Stats

$7.83

-$0.07(-0.97%)

At close: Jul 24 4:00 PM EDT

$7.83

-$0.07(-0.97%)

Day’s Range― - ―

52-Week Range$5.67 - $33.83

Previous Close$7.11

Volume11.05K

Average Volume (3M)8.37K

Market Cap

$52.15M

Enterprise Value$69.64

Total Cash (Recent Filing)$69.68M

Total Debt (Recent Filing)$3.67M

Price to Earnings (P/E)―

Beta4.94

Next Earnings

Nov 16, 2026

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.47

Shares Outstanding6,781,976

10 Day Avg. Volume7,210

30 Day Avg. Volume8,366

Financial Highlights & Ratios

PEG Ratio0.17

Price to Book (P/B)0.64

Price to Sales (P/S)0.00

P/FCF Ratio-2.00

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.17

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash CushionReported cash balance provides a downside cushion, creating a cash-backed floor that can absorb operating losses while strategic options are explored.

Reduced Cash BurnReported cash suggests cash burn should contract materially, which lowers pressure on reserves and extends the company’s financial runway for pursuing options.

Strategic Alternatives OpportunityManagement evaluation of strategic alternatives positions the company as a cash-backed option that could gain value from a sale, license, or partnership of remaining assets.

Bears Say

Financing And Dilution RiskWith no clear catalysts to support a re-rating, continued cash burn could necessitate new financing, creating dilution risk that would further pressure the stock.

Lead Program TerminationDiscontinuation of AXN-2510 removes the company's primary value driver and forces a full reset of the investment thesis by erasing the core clinical narrative.

Pipeline Valuation ResetLoss of the lead asset effectively resets pipeline value toward zero, leaving the equity reliant largely on cash rather than future product revenue potential.

Instil Bio News

Instil Bio Shareholders Back Directors and Auditor at Meeting

Instil Bio ( ($TIL) ) just unveiled an update. Instil Bio, Inc. reported that on June 11, 2026...

3M ago

TIL

Instil Bio Faces Heightened Cybersecurity Threats as Data Breach Risks Jeopardize Clinical Trials and Long-Term Strategy

Instil Bio, Inc. (TIL) has disclosed a new risk, in the Cyber Security category. An external analysis indicates...

5M ago

TIL

Instil Bio, Inc. (TIL) Q4 Earnings Cheat Sheet

Instil Bio, Inc. (TIL) is scheduled to report 4th quarter earnings on 03/10/2026. Regarding Q4 estimates, Wall Street...

6M ago

TIL

Instil Bio downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor downgraded Instil Bio (TIL) to Neutral from Buy without a price target saying...

8M ago

TIL

Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco

Instil Bio ( ($TIL) ) has shared an update. On January 5, 2026, Instil Bio’s subsidiary Axion Bio...

8M ago

TIL

Baird downgrades Instil Bio on discontinuation of AXN-2510

Baird analyst Jack Allen downgraded Instil Bio (TIL) to Neutral from Outperform with a price target of $7,...

8M ago

TIL

Instil Bio downgraded to Neutral from Outperform at Baird

Baird downgraded Instil Bio (TIL) to Neutral from Outperform with a price target of $7, down from $180,...

8M ago

TIL

Instil Bio’s Axion discontinues clinical development of AXN-2510

Instil Bio (TIL) announced that Axion Bio, a wholly-owned subsidiary of Instil, has decided to discontinue clinical development...

8M ago

TIL

Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year

As of September 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of...

10M ago

TIL

Instil Bio’s AXN-2510 Study: A Promising Step in Cancer Treatment

Instil Bio, Inc. (($TIL)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled...

10M ago

TIL

Citizens JMP healthcare analysts hold an analyst/industry conference call

Analyst discuss the evolving landscape in Non-Small Cell Lung Cancer (NSCLC) (relevant companies SMMT TIL CBIO IMMP NVLT)...

11M ago

TIL

CBIO

Instil Bio’s AXN-2510: Promising Data and Valuation Gap Justify Buy Rating

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Instil Bio and keeping the price target...

12M ago

TIL

Instil Bio announces ImmuneOnco presentation of ‘2510 monotherapy data

Instil Bio (TIL) announced that ImmuneOnco Biopharmaceuticals presented preliminary efficacy and safety data of ‘2510 as monotherapy in...

12M ago

TIL

Instil Bio’s Promising Outlook: Buy Rating Supported by Successful Trials and Market Potential

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio today and set a price target...

1y ago

TIL

TIL FAQ

What was Instil Bio’s price range in the past 12 months?

Instil Bio lowest stock price was $5.67 and its highest was $33.83 in the past 12 months.

What is Instil Bio’s market cap?

Instil Bio’s market cap is $52.15M.

When is Instil Bio’s upcoming earnings report date?

Instil Bio’s upcoming earnings report date is Nov 16, 2026 which is in 74 days.

How were Instil Bio’s earnings last quarter?

Instil Bio released its earnings results on Aug 13, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.28.

Is Instil Bio overvalued?

According to Wall Street analysts Instil Bio’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Instil Bio pay dividends?

Instil Bio does not currently pay dividends.

What is Instil Bio’s EPS estimate?

Instil Bio’s EPS estimate is -0.17.

How many shares outstanding does Instil Bio have?

Instil Bio has 6,781,976 shares outstanding.

What happened to Instil Bio’s price movement after its last earnings report?

Instil Bio reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went up 1.513%.

Which hedge fund is a major shareholder of Instil Bio?

Currently, no hedge funds are holding shares in TIL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Instil Bio Stock Smart Score

Underperform

Hedge Fund Trend

Increased

By 5.1K Shares
Last Quarter.

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-14.41%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Instil Bio

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.